LEADS BIOLABS-B (09887.HK): Presents LBL-024 Data at Jefferies
NewTimeSpace News: On 19 November 2026, Nanjing Leads Biolabs Co., Ltd. (stock code: 9887) announced on a voluntary basis that founder, chairman and chief executive Dr Kang Xiaoqiang was invited to the 2026 Jefferies Global Healthcare Conference in London, where he presented the latest clinical and safety data for the company's independently developed LBL-024, an anti-PD-L1/4-1BB bispecific antibody.
The company said LBL-024 has demonstrated breakthrough efficacy across seven tumour types and in five immunologically cold tumour types, with more than 800 patients treated and no dose-limiting toxicity observed. In a pivotal single-agent registration study in extra-pulmonary neuroendocrine carcinoma, median overall survival was 8.7 months versus historical data of about three to four months, while the objective response rate in first-line biliary tract carcinoma was 70.0%.
The company disclosed for the first time plans to launch several antibody-drug conjugate combination regimens in 2027, including combinations with its self-developed bispecific ADCs and T-cell engager ADCs. The first indication for LBL-024 is expected to be approved in the first half of 2027.
The company issued the warning statement required under Rule 18A.05 of the Listing Rules, saying it cannot guarantee that LBL-024 will be successfully developed or ultimately marketed.
- LEADS BIOLABS-B (09887.HK): Chairman Plans HKD 20M H-Share Purchase
- LEADS BIOLABS-B (09887.HK): LBL-047 completes first SLE patient dosing in Phase I Part B
- LEADS BIOLABS-B (09887.HK): LBL-024 data presented at ESMO 2026, 3L EP-NEC median OS 8.7 months
- LEADS BIOLABS-B (09887.HK): Updated LBL-034 Data in RRMM Presented at ESMO
- LEADS BIOLABS-B (09887.HK): Six Abstracts on Weilixin and LBL-034 Published at ESMO 2026; Three Chosen for Oral Presentations